Curaleaf Holdings Inc (CURLF)

The cannabis sector is experiencing a historic "Santa Claus rally" this December, with stock prices surging across the board following a transformative shift in federal policy. Today, December 19, 2025, markets are still reeling from yesterday’s decisive executive action aimed at ending the federal gridlock that has plagued the

In a move that has sent shockwaves through the global financial markets, the cannabis sector is currently navigating a period of unprecedented volatility following a landmark regulatory shift. On December 18, 2025, President Donald Trump signed a historic Executive Order directing the Attorney General to expedite the reclassification of marijuana

The company and many of its peers saw dramatic lifts on the back of new Presidential remarks.

The company opened the doors of a new dispensary, while lawmakers in Congress submitted a new pot reform resolution.

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare.

Congress appears set to end the record-long government shutdown, but a controversial provision tucked into the spending bill is sparking alarm across the hemp and cannabis industry.

Tilray Brands (NASDAQ: TLRY) has once again found itself at the epicenter of market volatility, with its stock experiencing a significant dip this past week, closing near $1.34 USD as of early November 2025. This downturn comes amidst a complex tapestry of mixed signals, leaving investors and analysts grappling

One marijuana industry insider says Monday's Truth Social video is a "trial balloon" testing support for marijuana legalization.

Marijuana legalization may be coming, but does this make Curaleaf stock an automatic buy?

New York, NY – September 25, 2025 – Tilray Brands Inc. (NASDAQ: TLRY) saw its stock tumble by a significant -5.21% on Thursday, September 25, 2025, as investor confidence continued to erode under the weight of persistent FDA approval uncertainties and a challenging regulatory landscape. This latest decline signals growing apprehension

A study conducted in Europe advanced arguments for marijuana law reform around the world.

The American company's stock is making a splash north of our border.

At times, the prospects for pot legalization seem to dim.

There was good news about one of its less-popular products.

If cannabis is no longer a Schedule I drug, that could result in significant tax savings for many marijuana producers.

A group of federal advisors seem to be focused on the negative effects of cannabis.

Investors were cheered about movement on the legalization front.

Cannabis stocks and ETFs skyrocketed after Trump hinted at reclassifying marijuana. Tilray surged 35% in 2 days. Other top performers included Trulieve, Tilray, Curaleaf, and Canopy Growth. This shift could ease federal regulations and improve the industry's growth potential.

The momentum from this cannabis company's Q2 update continues.

They found quite a bit to like in the marijuana company's latest quarterly earnings release.

It had a double-digit day in the run-up to its Wednesday quarterly earnings release.